Stablepharma awarded the highly competitive and prestigious EIC Accelorator Grant of €2.5mStablepharma Receives MHRA Approval for Phase 1 Trial of Fridge-Free Tetanus and Diphtheria (Td) Vaccine
EIC (European Innovation Council) Accelerator Grant 2025 Awarded to Stablepharma - EIC Website - News
The Reality
A child dying every 20 seconds is an unacceptable statistic. Stablepharma is committed to launching the world’s first fridge-free vaccines, reducing the need for the cold chain and enabling stockpiling anywhere in the world.
Fridge-Free Vaccines
Our novel StablevaX™ technology is designed to dramatically enhance the performance of existing and new vaccines, thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration.
Expanding Access
Stablepharma’s fridge-free vaccines can help expand access to patients and increase the success of immunisation programmes.
Latest Press Coverage on Stablepharma
Stablepharma Technology
StablevaX™ is a novel technology that enhances thermostability of existing approved vaccines, following current WHO protocols.
Zero Refrigeration
StablevaX™ technology eliminates the need for refrigeration/cold chain entirely, extending shelf-life and enabling strategic stockpiling.
Existing Administration Practice
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice.
Environmental Impact
StablevaX™ technology reduces the environmental impact of the global cold chain.
We use our StablevaX™ technology to reformulate and thermo-stabilise existing and new vaccines in partnership with vaccine manufacturers. Through this, we reduce the need for the cold-chain, reduce wastage, costs and carbon emissions. To find out more:
